ERBB2 and breast carcinoma: EMPD also shares some molecular features with breast cancer and MPD, with overexpression of HRs (estrogen receptor [ER] and progesterone receptor [PgR]) and/or HER2 (∼10% and ∼30% of patients with EMPD, respectively).1–5